Kariya Pharmaceuticals Overview
- Founded
- 2018
- Status
- Private
- Latest Deal Type
- Early Stage VC
- Latest Deal Amount
- $591K
- Investors
- 3
Kariya Pharmaceuticals General Information
Description
Developer and researcher of first-in-class drugs designed to slow the progression of neurodegenerative diseases. The company's drug consists of dual incretin receptors, enabling patients to treat Parkinson's and Alzheimer's diseases.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Primary Office
- Ole Maaløes Vej 3
- 2200 Copenhagen
- Denmark
Kariya Pharmaceuticals Timeline
Kariya Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC | 10-Dec-2019 | $591K | 00.000 | Completed | Startup | |
| 2. Accelerator/Incubator | 29-May-2019 | 00.000 | Completed | Startup | ||
| 1. Accelerator/Incubator | 07-Feb-2019 | $1.53M | $1.53M | Completed | Startup |
Kariya Pharmaceuticals Executive Team (3)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Ian Laquian | Co-Founder & Chief Executive Officer | ||
| Christian Hölscher | Co-Founder & Chief Scientific Officer | ||
| Mikael Thomsen Ph.D | Co-Founder & CDO |
Kariya Pharmaceuticals Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Innovationsfonden | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Copenhagen Bio Science Park | Accelerator/Incubator | Minority | 000 0000 | 000000 0 | |
| BioInnovation Institute (BII) | Accelerator/Incubator | Minority | 000 0000 | 000000 0 |